Lexicon Pharmaceuticals Inc (LXRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lexicon Pharmaceuticals Inc (LXRX) has a cash flow conversion efficiency ratio of -0.073x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.73 Million) by net assets ($202.86 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LXRX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Lexicon Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Lexicon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lexicon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lexicon Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunan Airbluer Environmental Protection Technology Co. Ltd.
SHE:301259
|
N/A |
|
Jiangsu High Hope International Group Corp
SHG:600981
|
-0.062x |
|
Ripley Corp
SN:RIPLEY
|
-0.016x |
|
Standard Motor Products Inc
NYSE:SMP
|
0.132x |
|
Changchun Faway Automobile Components Co Ltd
SHG:600742
|
0.066x |
|
CCP Contact Probe Co Ltd
TWO:6217
|
-0.031x |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
0.076x |
|
Jastrzebska Spotka Weglowa SA
WAR:JSW
|
0.130x |
Annual Cash Flow Conversion Efficiency for Lexicon Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Lexicon Pharmaceuticals Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Lexicon Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $107.54 Million | $-67.85 Million | -0.631x | +48.49% |
| 2024-12-31 | $145.95 Million | $-178.78 Million | -1.225x | +29.55% |
| 2023-12-31 | $93.11 Million | $-161.90 Million | -1.739x | -129.21% |
| 2022-12-31 | $117.12 Million | $-88.85 Million | -0.759x | +0.97% |
| 2021-12-31 | $113.59 Million | $-87.02 Million | -0.766x | +16.22% |
| 2020-12-31 | $156.37 Million | $-142.97 Million | -0.914x | -194.08% |
| 2019-12-31 | $117.10 Million | $113.81 Million | 0.972x | -82.73% |
| 2018-12-31 | $-26.41 Million | $-148.61 Million | 5.628x | +258.17% |
| 2017-12-31 | $52.10 Million | $-185.39 Million | -3.558x | -218.90% |
| 2016-12-31 | $157.40 Million | $-175.63 Million | -1.116x | -272.62% |
| 2015-12-31 | $285.85 Million | $184.78 Million | 0.646x | +342.78% |
| 2014-12-31 | $284.02 Million | $-75.62 Million | -0.266x | +50.26% |
| 2013-12-31 | $170.16 Million | $-91.08 Million | -0.535x | -51.11% |
| 2012-12-31 | $266.68 Million | $-94.46 Million | -0.354x | -19.86% |
| 2011-12-31 | $297.57 Million | $-87.94 Million | -0.296x | +11.37% |
| 2010-12-31 | $247.02 Million | $-82.37 Million | -0.333x | +38.76% |
| 2009-12-31 | $163.50 Million | $-89.02 Million | -0.544x | -11.53% |
| 2008-12-31 | $195.83 Million | $-95.60 Million | -0.488x | -88.23% |
| 2007-12-31 | $286.57 Million | $-74.32 Million | -0.259x | +61.03% |
| 2006-12-31 | $85.50 Million | $-56.91 Million | -0.666x | -343.62% |
| 2005-12-31 | $85.80 Million | $23.44 Million | 0.273x | +178.62% |
| 2004-12-31 | $121.59 Million | $-42.26 Million | -0.348x | -648.61% |
| 2003-12-31 | $166.22 Million | $-7.72 Million | -0.046x | +72.61% |
| 2002-12-31 | $169.90 Million | $-28.79 Million | -0.169x | -105.70% |
| 2001-12-31 | $218.37 Million | $-17.99 Million | -0.082x | -1039.20% |
| 2000-12-31 | $207.63 Million | $-1.50 Million | -0.007x | +99.38% |
| 1999-12-31 | $8.20 Million | $-9.60 Million | -1.171x | -- |
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more